Kwadwo A. Oduro

Kwadwo A. Oduro


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in Laboratory Investigation
Verified
Journal Article
Open access
KOKwadwo A. Oduro
Kwadwo A. Oduro
TSTheresa Spivey
Theresa Spivey
EMErika M. Moore
Erika M. Moore
HMHoward Meyerson
Howard Meyerson
JYJennifer Yoest
Jennifer Yoest
NSNavid Sadri
Navid Sadri
The ability to detect low-level disease is key to our understanding of clonal heterogeneity in acute myeloid leukemia (AML) and residual disease that elude conventional assays and seed relapse. We developed a high-sensitivity next-generation sequencing (HS-NGS) clinical assay, able to reliably detect low levels (1 × 10-5) of FLT3-ITD, a frequent, therapeutically targetable and prognostically relevant mutation in AML. By applying this assay to 289 longitudinal samples from 62 patients at initial diagnosis and/or clinical follow-up (mean follow-up of 22 months), we reveal the frequent occurrence of FLT3-ITD subclones at diagnosis and demonstrate a significantly decreased relapse risk when FLT3-ITD is cleared after induction or thereafter. We perform pairwise sequencing of diagnosis and relapse samples from 23 patients to uncover more detailed patterns of FLT3-ITD clonal evolution at relapse than is detectable by less-sensitive assays. Finally, we show that rising ITD level during consecutive biopsies is a harbinger of impending relapse. Our findings corroborate the emerging clinical utility of high-sensitivity FLT3-ITD testing and expands our understanding of clonal dynamics in FLT3-ITD-positive AML.

23 October 2023 in British Journal of Haematology
Verified
Journal Article
Open access
CGCatherine K. Gestrich
Catherine K. Gestrich
SLShanelle J. De Lancy
Shanelle J. De Lancy
AKAdam Kresak
Adam Kresak
HMHoward Meyerson
Howard Meyerson
IPIrina Pateva
Irina Pateva
KOKwadwo A. Oduro
Kwadwo A. Oduro
Summary: Therapeutic management and prognostication for patients with B‐acute lymphoblastic leukaemia (B‐ALL) require appropriate disease subclassification. BCR::ABL1‐like B‐ALL is unique in that it is defined by a gene expression profile similar to BCR::ABL1+ B‐ALL rather than a unifying recurrent translocation. Current molecular/cytogenetic techniques to identify this subtype are expensive, not widely accessible, have long turnaround times and/or require an adequate liquid biopsy. We have studied a total of 118 B‐ALL cases from three institutions in two laboratories to identify surrogates for BCR::ABL1+/like B‐ALL. We report that immunoglobulin joining chain (IGJ) and spermatogenesis associated serine‐rich 2‐like (SPATS2L) immunohistochemistry (IHC) sensitively and specifically identify BCR::ABL1+/like B‐ALL. IGJ IHC positivity has a sensitivity of 83%, a specificity of 95%, a positive predictive value (PPV) of 89% and a negative predictive value (NPV) of 90%. SPATS2L staining has similar sensitivity and NPV but lower specificity (85%) and PPV (70%). The presence of either IGJ or SPATS2L staining augments the sensitivity (93%) and NPV (95%). While these findings would need to be validated in larger studies, they suggest that IGJ and/or SPATS2L IHC may be utilized in identifying BCR::ABL1‐like B‐ALL or in selecting B‐ALL cases for confirmatory molecular/genetic testing, particularly in resource‐limited settings.

5 April 2023 in Human Pathology
Verified
Journal Article
Closed access
CGCatherine K. Gestrich
Catherine K. Gestrich
SLShanelle J. De Lancy
Shanelle J. De Lancy
AKAdam Kresak
Adam Kresak
MSMohamad G. Sinno
Mohamad G. Sinno
AYAkua Yalley
Akua Yalley
KOKwadwo A. Oduro
Kwadwo A. Oduro

26 March 2022 in Genes
Verified
Journal Article
Open access
PDF file
AJAudrey Nadine Jajosky
Audrey Nadine Jajosky
AMAnna L. Mitchell
Anna L. Mitchell
MAMahmut Akgul
Mahmut Akgul
SSShashirekha Shetty
Shashirekha Shetty
JYJennifer M. Yoest
Jennifer M. Yoest
KOKwadwo A. Oduro
Kwadwo A. Oduro
Germline disruptive variants in Protection of Telomeres 1 (POT1) predispose to a wide variety of cancers, including melanoma, chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, myeloproliferative neoplasms, and glioma. We report the first case of splenic marginal zone lymphoma (SMZL) arising in a patient with a germline POT1 variant: a 65-year-old male with an extensive history of cancer, including melanoma and papillary thyroid carcinoma, who presented with circulating atypical lymphocytosis. Bone marrow biopsy revealed 20% involvement by a CD5−CD10− B-cell lymphoma that was difficult to classify. During the clinical workup of his low-grade lymphoma, targeted next-generation sequencing (NGS) identified POT1 p.I49Mfs*7 (NM_015450:c. 147delT) at a variant allele frequency (VAF) of 51%. NGS of skin fibroblasts confirmed the POT1 variant was germline. This likely pathogenic POT1 loss-of-function variant has only been reported once before as a germline variant in a patient with glioma and likely represents one of the most deleterious germline POT1 variants ever linked to familial cancer. The spectrum of cancers associated with germline pathogenic POT1 variants (i.e., autosomal dominant POT1 tumor predisposition syndrome) should potentially be expanded to include SMZL, a disease often associated with the loss of chromosome 7q: the location of the POT1 genetic locus (7q31.33).

24 November 2022 in Blood
Verified
Journal Article
Open access
PDF file
SLShanelle De Lancy
Shanelle De Lancy
KOKwadwo A. Oduro
Kwadwo A. Oduro